Johnson & Johnson has asked U.S. health regulators to authorize a booster dose for its Covid-19 vaccine, citing studies showing it improved protection among adults who previously received a single shot.
The Food and Drug Administration could decide on J&J’s request within weeks. The agency has scheduled an Oct. 15 meeting of an advisory panel to review the evidence of the need for a booster, and to recommend whether the agency should authorize one.
